Logo of Oncosil Medical (ASX:OSL)Latest Oncosil Medical (ASX:OSL) News

Page 1
Page 1 of 6

Market Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Explorers led the strongest gains, while biotech, payments and gold producers suffered the biggest falls. Takeover bids, project funding and trial results drove sharp moves across the market.

Resources stayed busy, but investors punished companies with weak cash positions, delayed approvals or disappointing operating updates.
Logan Eniac
31 Oct 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

OncoSil adds FDA approval to 45.8% revenue growth as U.S. launch approaches

OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.
Victor Sage
30 Oct 2026

OncoSil grows revenue 44% as regulatory wins collide with funding pressure

OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
27 Oct 2026

Healthcare Wrap - Week 37 (7 Sept -> 11 Sept) 2026

Neurizon and Clever Culture Systems led the week with 35.71% gains, while CONNEQT also rose despite giving back part of its reopening move.
Biotech trial funding, device manufacturing and healthcare launches shaped investor decisions across the sector.
Logan Eniac
12 Sept 2026

OncoSil clears key quality hurdle for Sydney manufacturing facility

OncoSil Medical has moved closer to local production after contract manufacturer Cyclotek secured ISO 13485 certification for its quality management system. Production at the Macquarie Park facility remains targeted for the end of 2Q FY27, subject to further regulatory approval.
Victor Sage
9 Sept 2026

OncoSil Medical raises $5.6 million as commercial launch moves into view

OncoSil Medical has secured $5.6 million from its three largest institutional investors to fund commercial launches of its OncoSil device in the United States and Australia. The commitments follow FDA and TGA approvals and would lift pro-forma cash to $12.1 million once completed.
Ada Torres
7 Sept 2026

Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.
Logan Eniac
29 Aug 2026

OncoSil Medical Reports FY26 Revenue Surge and FDA Approval Milestone

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.
Ada Torres
28 Aug 2026

Market Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Gold, rare earths and energy shares led a busy week, while major company results brought large gains and steep sell-offs. Corporate deals, new project studies and rising dividends drew buyers, but some stocks fell despite stronger earnings.
Logan Eniac
22 Aug 2026

Healthcare Wrap - Week 34 (17 Aug -> 21 Aug) 2026

Healthcare shares delivered a mixed week, with strong gains at AVITA Medical, Australian Clinical Labs and CSL despite very different company results.
Investors also weighed new US approvals, clinical trial progress, funding needs and rising sales across the sector.
Logan Eniac
22 Aug 2026

OncoSil Medical Secures FDA Approval for Rare Bile Duct Cancer Device

OncoSil Medical has won FDA Humanitarian Device Exemption approval for its OncoSil™ device to treat distal cholangiocarcinoma, opening a US market estimated at A$80 million annually.
Ada Torres
17 Aug 2026